Literature DB >> 12641444

Inorganic and dimethylated arsenic species induce cellular p53.

Maria Filippova1, Penelope J Duerksen-Hughes.   

Abstract

Arsenic compounds are known for their ability both to cause and to treat human cancers, although the molecular mechanisms underlying these actions are incompletely understood. The simplest explanation is that arsenic causes DNA damage that leads to mutations. However, the majority of scientific evidence indicates that arsenic is not a genotoxin or DNA-damaging agent. DNA damage typically leads to cellular responses designed to minimize the replication of damaged DNA, such as the induction of p53, and p53 induction has therefore been used as an indicator of DNA damage. Because this approach can be applied to human cells and does not rely on a specific, heritable mutation occurring at a particular site, it seemed possible that this method could detect DNA damage that was undetectable using other techniques. To examine the genotoxic potential of arsenic compounds, therefore, seven of these compounds (sodium arsenite, sodium arsenate, methyloxoarsine, iododimethylarsine, disodium methyl arsonate, dimethylarsinic acid, and arsenic trioxide) were tested for their ability to increase the cellular level of p53 as measured by ELISA. Of this group, arsenic trioxide was the strongest inducer of cellular p53, while dimethylarsinic acid, iododimethylarsine, and sodium arsenite also caused p53 induction in a dose- and time-dependent manner. Sodium arsenate, as well as the two monomethyl compounds tested, methyloxoarsine and disodium methyl arsonate, did not cause detectable increases in cellular p53. Our results indicate, therefore, that cells respond to several of these arsenic compounds as they do to chemicals that damage DNA, suggesting that exposure of cells to these compounds does in fact cause DNA damage. Such damage could then result in mutations and the observed development of cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12641444     DOI: 10.1021/tx025606a

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  13 in total

1.  Toxicity of depleted uranium complexes is independent of p53 activity.

Authors:  Ellie Heintze; Camille Aguilera; Malia Davis; Avery Fricker; Qiang Li; Jesse Martinez; Matthew J Gage
Journal:  J Inorg Biochem       Date:  2010-10-29       Impact factor: 4.155

2.  Mutually exclusive subsets of BH3-only proteins are activated by the p53 and c-Jun N-terminal kinase/c-Jun signaling pathways during cortical neuron apoptosis induced by arsenite.

Authors:  Hon Kit Wong; Michael Fricker; Andreas Wyttenbach; Andreas Villunger; Ewa M Michalak; Andreas Strasser; Aviva M Tolkovsky
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

3.  The interaction between human papillomavirus type 16 and FADD is mediated by a novel E6 binding domain.

Authors:  Sandy S Tungteakkhun; Maria Filippova; Jonathan W Neidigh; Nadja Fodor; Penelope J Duerksen-Hughes
Journal:  J Virol       Date:  2008-07-16       Impact factor: 5.103

4.  Tumour suppressor p53 down-regulates the expression of the human hepatocyte nuclear factor 4alpha (HNF4alpha) gene.

Authors:  Yutaka Maeda; Wendy W Hwang-Verslues; Gang Wei; Takuya Fukazawa; Mary L Durbin; Laurie B Owen; Xuan Liu; Frances M Sladek
Journal:  Biochem J       Date:  2006-12-01       Impact factor: 3.857

5.  The small splice variant of HPV16 E6, E6, reduces tumor formation in cervical carcinoma xenografts.

Authors:  Maria Filippova; Whitney Evans; Robert Aragon; Valery Filippov; Vonetta M Williams; Linda Hong; Mark E Reeves; Penelope Duerksen-Hughes
Journal:  Virology       Date:  2014-01-01       Impact factor: 3.616

6.  DNA damage induces down-regulation of UDP-glucose ceramide glucosyltransferase, increases ceramide levels and triggers apoptosis in p53-deficient cancer cells.

Authors:  Teka-Ann S Haynes; Valery Filippov; Maria Filippova; Jun Yang; Kangling Zhang; Penelope J Duerksen-Hughes
Journal:  Biochim Biophys Acta       Date:  2012-02-11

7.  Therapeutic Potential of Arsenic Trioxide (ATO) in Treatment of Hepatocellular Carcinoma: Role of Oxidative Stress in ATO-Induced Apoptosis.

Authors:  Erika B Dugo; Clement G Yedjou; Jacqueline J Stevens; Paul B Tchounwou
Journal:  Ann Clin Pathol       Date:  2017-01-04

8.  p53 regulates Hsp90beta during arsenite-induced cytotoxicity in glutathione-deficient cells.

Authors:  Geetha M Habib
Journal:  Arch Biochem Biophys       Date:  2008-10-26       Impact factor: 4.013

9.  Splicing and splice factor SRp55 participate in the response to DNA damage by changing isoform ratios of target genes.

Authors:  Valery Filippov; Erin L Schmidt; Maria Filippova; Penelope J Duerksen-Hughes
Journal:  Gene       Date:  2008-05-23       Impact factor: 3.688

10.  BRCA2-dependent homologous recombination is required for repair of Arsenite-induced replication lesions in mammalian cells.

Authors:  Songmin Ying; Katie Myers; Sarah Bottomley; Thomas Helleday; Helen E Bryant
Journal:  Nucleic Acids Res       Date:  2009-06-23       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.